Synthetic HLA binding WT-1 peptide analogues and uses thereof
AssigneeMemorial Sloan Kettering Cancer Center
InventorsDavid A. Scheinberg, Javier Pinilla-Ibarz
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a synthetic peptide comprising a sequence of amino acids containing at least a segment that is an analogue of a native peptide that specifically binds to HLA A0201 or HLA A0301 molecules on a cell characteristic of a pathophysiologic state in a mammal. The synthetic peptide may be derived from native peptides comprising a breakpoint region of the WT1 protein.
Claims17
A synthetic WT-1 peptide, comprising a sequence of amino acids that is an analogue peptide of a native WT-1 peptide, wherein said analogue specifically binds to HLA A0201 or HLA A0301 molecules on a human cell, wherein the analogue peptide sequence is GLRRGIQDV (SEQ ID NO:
- 28).
A synthetic WT-1 peptide consisting of the amino acid sequence GLRRGIQDV (SEQ ID NO:
- 28).
Dependencies are inferred from the claim text.